Recent studies on the role of brain peptides in control of anterior pituitary hormone secretion.
Recent work in our laboratory on the role of peptides to influence release of pituitary hormones by direct action on the gland and also some of the interactions of these peptides at the hypothalamic level to alter release of pituitary hormones will be reviewed. Considerable evidence from hypothalamic stimulation and lesion studies suggests the existence of a separate FSH-releasing factor (FSHRF). We have been able to purify a bioactive FSHRF which appears to be distinct from LHRH. Consequently, we believe that a distinct FSHRF will ultimately be isolated. With regard to prolactin, it is now clear that it is under dual control by both prolactin-inhibiting (PI) and prolactin-releasing factors (PRF). Although dopamine acts as a PIF, our recent fractionation studies indicate the existence of a peptidic PIF in hypothalamic extracts which can be separated from dopamine and GABA. The peptidic PIF is eluted from Sephadex in the same position originally described by us a number of years ago. Thus, inhibitory control is probably mediated by a combination of factors which would include dopamine, possibly GABA and a peptidic PIF. A number of peptides have been shown to have PRF activity which include TRF and also VIP. In recent studies, we have shown a prolactin-releasing action of oxytocin on male hemipituitaries or dispersed pituitary cells. Furthermore, high doses of oxytocin given intravenously released prolactin in male rats. There is a correlation between estrogen-induced prolactin release and an increase in plasma oxytocin and a correlation between suckling-induced oxytocin and prolactin release. These results suggest that oxytocin may be an important PRF.(ABSTRACT TRUNCATED AT 250 WORDS)
D000818:Animals; D004298:Dopamine / Q000502:physiology; D005246:Feedback; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D007987:Gonadotropin-Releasing Hormone / Q000502:physiology; D013006:Growth Hormone / Q000378:metabolism; D013007:Growth Hormone-Releasing Hormone / Q000502:physiology; D006801:Humans; D007031:Hypothalamus / Q000502:physiology*; D007986:Luteinizing Hormone / Q000378:metabolism; D009037:Motilin / Q000502:physiology; D009419:Nerve Tissue Proteins / Q000502:physiology*; D010121:Oxytocin / Q000502:physiology; D010903:Pituitary Gland, Anterior / Q000378:metabolism*; D010907:Pituitary Hormones / Q000378:metabolism*; D011388:Prolactin / Q000037:antagonists & inhibitors / Q000378:metabolism; D013004:Somatostatin / Q000502:physiology; D013973:Thyrotropin-Releasing Hormone / Q000502:physiology; D014660:Vasoactive Intestinal Peptide / Q000502:physiology; D005680:gamma-Aminobutyric Acid / Q000502:physiology
D009419:Nerve Tissue Proteins; D010907:Pituitary Hormones; D007987:Gonadotropin-Releasing Hormone; D014660:Vasoactive Intestinal Peptide; D010121:Oxytocin; D013004:Somatostatin; D009037:Motilin; D005680:gamma-Aminobutyric Acid; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone; D004298:Dopamine